Intellia Therapeutics, Inc. (NASDAQ:NTLA) Receives $54.94 Average Target Price from Analysts

Intellia Therapeutics, Inc. (NASDAQ:NTLA) has earned a consensus rating of “Moderate Buy” from the eighteen research firms that are presently covering the stock, Marketbeat.com reports. Six investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $54.94.

NTLA has been the subject of a number of recent analyst reports. Stifel Nicolaus lowered their price objective on shares of Intellia Therapeutics from $80.00 to $64.00 and set a “buy” rating for the company in a research report on Wednesday, September 11th. Royal Bank of Canada reissued an “outperform” rating and issued a $54.00 price objective on shares of Intellia Therapeutics in a research report on Thursday, September 19th. Citigroup reduced their price target on Intellia Therapeutics from $25.00 to $19.00 and set a “neutral” rating for the company in a research report on Friday, October 25th. William Blair reissued a “neutral” rating and issued a $14.00 price objective on shares of Intellia Therapeutics in a research report on Monday, November 18th. Finally, Barclays decreased their price objective on shares of Intellia Therapeutics from $76.00 to $55.00 and set an “overweight” rating on the stock in a report on Friday, November 8th.

Insider Activity at Intellia Therapeutics

In other news, CAO Michael P. Dube sold 2,012 shares of the stock in a transaction on Wednesday, October 2nd. The stock was sold at an average price of $19.01, for a total value of $38,248.12. Following the completion of the transaction, the chief accounting officer now directly owns 47,012 shares in the company, valued at approximately $893,698.12. This represents a 4.10 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 3.20% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Intellia Therapeutics

Several large investors have recently bought and sold shares of NTLA. Blue Trust Inc. boosted its position in Intellia Therapeutics by 1,664.3% during the 2nd quarter. Blue Trust Inc. now owns 1,482 shares of the company’s stock worth $33,000 after buying an additional 1,398 shares during the period. EverSource Wealth Advisors LLC grew its stake in shares of Intellia Therapeutics by 763.5% in the second quarter. EverSource Wealth Advisors LLC now owns 1,753 shares of the company’s stock worth $39,000 after purchasing an additional 1,550 shares during the last quarter. Eastern Bank acquired a new stake in Intellia Therapeutics in the third quarter valued at $41,000. First Horizon Advisors Inc. raised its position in Intellia Therapeutics by 22.1% during the 2nd quarter. First Horizon Advisors Inc. now owns 2,604 shares of the company’s stock worth $58,000 after purchasing an additional 472 shares during the last quarter. Finally, Values First Advisors Inc. bought a new stake in shares of Intellia Therapeutics in the 3rd quarter valued at about $54,000. 88.77% of the stock is currently owned by institutional investors.

Intellia Therapeutics Trading Down 4.9 %

Shares of NASDAQ NTLA opened at $12.90 on Wednesday. The company has a 50-day moving average of $16.23 and a two-hundred day moving average of $20.70. Intellia Therapeutics has a 1-year low of $12.47 and a 1-year high of $34.87. The company has a market cap of $1.31 billion, a PE ratio of -2.37 and a beta of 1.76.

Intellia Therapeutics (NASDAQ:NTLA) last issued its earnings results on Thursday, November 7th. The company reported ($1.34) EPS for the quarter, beating the consensus estimate of ($1.37) by $0.03. The business had revenue of $9.10 million for the quarter, compared to the consensus estimate of $8.28 million. During the same quarter in the previous year, the firm posted ($1.38) EPS. The business’s revenue was down 24.1% on a year-over-year basis. As a group, equities research analysts forecast that Intellia Therapeutics will post -5.12 earnings per share for the current year.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.